Wird geladen...
Bioengineering hemophilia A–specific microvascular grafts for delivery of full-length factor VIII into the bloodstream
Hemophilia A (HA) is a bleeding disorder caused by mutations in the F8 gene encoding coagulation factor VIII (FVIII). Current treatments are based on regular infusions of FVIII concentrates throughout a patient’s life. Alternatively, viral gene therapies that directly deliver F8 in vivo have shown p...
Gespeichert in:
| Veröffentlicht in: | Blood Adv |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6929393/ https://ncbi.nlm.nih.gov/pubmed/31851760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000848 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|